Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells by Tarja A Juopperi et al.
Juopperi et al. Molecular Brain 2012, 5:17
http://www.molecularbrain.com/content/5/1/17RESEARCH Open AccessAstrocytes generated from patient induced
pluripotent stem cells recapitulate features of
Huntington’s disease patient cells
Tarja A Juopperi1,2, Woon Ryoung Kim1,2, Cheng-Hsuan Chiang1,3, Huimei Yu1,2, Russell L Margolis2,4,
Christopher A Ross2,4, Guo-li Ming1,2,3* and Hongjun Song1,2,3*Abstract
Background: Huntington’s Disease (HD) is a devastating neurodegenerative disorder that clinically manifests as
motor dysfunction, cognitive impairment and psychiatric symptoms. There is currently no cure for this progressive
and fatal disorder. The causative mutation of this hereditary disease is a trinucleotide repeat expansion (CAG) in the
Huntingtin gene that results in an expanded polyglutamine tract. Multiple mechanisms have been proposed to
explain the preferential striatal and cortical degeneration that occurs with HD, including non-cell-autonomous
contribution from astrocytes. Although numerous cell culture and animal models exist, there is a great need for
experimental systems that can more accurately replicate the human disease. Human induced pluripotent stem cells
(iPSCs) are a remarkable new tool to study neurological disorders because this cell type can be derived from
patients as a renewable, genetically tractable source for unlimited cells that are difficult to acquire, such as neurons
and astrocytes. The development of experimental systems based on iPSC technology could aid in the identification
of molecular lesions and therapeutic treatments.
Results: We derived iPSCs from a father with adult onset HD and 50 CAG repeats (F-HD-iPSC) and his daughter
with juvenile HD and 109 CAG repeats (D-HD-iPSC). These disease-specific iPSC lines were characterized by standard
assays to assess the quality of iPSC lines and to demonstrate their pluripotency. HD-iPSCs were capable of
producing phenotypically normal, functional neurons in vitro and were able to survive and differentiate into
neurons in the adult mouse brain in vivo after transplantation. Surprisingly, when HD-iPSCs were directed to
differentiate into an astrocytic lineage, we observed the presence of cytoplasmic, electron clear vacuoles in
astrocytes from both F-HD-iPSCs and D-HD-iPSCs, which were significantly more pronounced in D-HD-astrocytes.
Remarkably, the vacuolation in diseased astrocytes was observed under basal culture conditions without additional
stressors and increased over time. Importantly, similar vacuolation phenotype has also been observed in peripheral
blood lymphocytes from individuals with HD. Together, these data suggest that vacuolation may be a phenotype
associated with HD.
Conclusions: We have generated a unique in vitro system to study HD pathogenesis using patient-specific iPSCs.
The astrocytes derived from patient-specific iPSCs exhibit a vacuolation phenotype, a phenomenon previously
documented in primary lymphocytes from HD patients. Our studies pave the way for future mechanistic
investigations using human iPSCs to model HD and for high-throughput therapeutic screens.
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Huntington’s disease (HD) is a fatal, progressive, neuro-
degenerative disorder that affects approximately 1 in
10,000 people [1]. The disease clinically manifests as
motor dysfunction, typified by involuntary movements,
cognitive abnormalities and psychiatric disturbances
[2]. The genetic defect for this autosomal dominant
disorder is a trinucleotide repeat expansion (CAG) in
exon 1 of huntingtin (HTT), which results in an
expanded polyglutamine tract at the N-terminal of the
HTT protein [3]. Proteolytic cleaving of the abnormal
HTT protein results in insoluble aggregates that form
characteristic inclusions within the nucleus and cyto-
plasm of affected cells [4,5]. Although the wild-type
HTT protein is ubiquitously expressed [6], there is a
preferential accumulation of the mutant HTT protein
in neurons, including medium spiny neurons of the
striatum [7]. Mutant HTT aggregates have also been
detected in other neural cell types such as astrocytes in
the brain of HD patients [8,9]. Regional neurodegen-
eration characterized by striatal degeneration and cor-
tical loss is a hallmark of HD pathology [10,11]. Other
areas of the brain, such as the hippocampus, are also
affected [12].
HD manifests in both a juvenile form that has a child-
hood onset, and a more common form that presents at
the middle age. Unaffected individuals have up to 35
CAG repeats within the HTT gene and HD is associated
with repeats of 36 or more [13]. There is an inverse cor-
relation with CAG repeat length and onset of disease,
with longer repeats (>55 CAG) associate more com-
monly with a juvenile onset [14]. Paternal inheritance of
the HTT mutation may result in CAG repeat length in-
stability and an increase in CAG repeat length [15,16].
Although HD is a defined genetic disorder and the
causative mutation was identified almost two decades
ago [3], the exact mechanism by which mutant HTT
results in neuronal degeneration has yet to be deter-
mined, and major therapeutic advances have been lack-
ing. Various in vitro cell culture systems [17,18] and
animal models [19,20] have been developed to investi-
gate HD pathogenesis and have provided numerous the-
ories, such as abnormal mitochondrial bioenergetics,
oxidative damage, transcriptional dysregulation and ab-
normal vesicle trafficking [2,5,21]. The potential role of
glia cells, such as astrocytes, in the pathogenesis of HD
is also being investigated [9,22-24]. For example, expres-
sion of HTT with expanded polyglutamine in astrocytes
has been shown to affect glutamate transport and ex-
acerbate neurological phenotypes in a mouse model of
HD [22,23]. The cholesterol defect is also observed in
astrocytes in multiple rodent models of HD [25]. A dir-
ect pathogenic role of astrocytes in the disease process
of patients remains unknown.The discovery of a combination of transcription factors
that could reprogram somatic cells into cells exhibiting
pluripotency has provided researchers with a revolutionary
tool to study human biology and diseases [26,27]. The
induced pluripotent stem cells (iPSCs) can be derived
from many somatic cell types, including easily accessible
dermal fibroblasts and peripheral blood lymphocytes
[28,29]. Similar to human embryonic stem cells (hESCs),
iPSCs can self-renew and expand indefinitely in culture
[27,30]. More importantly, they share the capacity to gen-
erate any cell types in the body, a property that is particu-
larly useful for the study of neurological diseases [31-35].
The pluripotency of iPSCs enables the production of neu-
rons and glia from healthy individuals and from patients
with diseases. This remarkable feature of iPSCs facilitates
the study of brain cell types that are difficult to obtain
from living individuals. Here we report the generation of
iPSCs from a male patient with an adult form of HD
(F-HD-iPSCs) and from his daughter with juvenile onset
HD (D-HD-iPSCs). Consistent with previous reports,
functional neurons can be derived from both HD-iPSCs
that are phenotypically normal. However, when astrocytes
were differentiated from these iPSCs, we identified a cellu-
lar vacuolation phenotype that has not been reported in
neural cells, but observed in patient lymphocytes with
HD. The ability of the HD-iPCSs to replicate a disease
relevant phenotype that is found in primary patient tissues
supports the use of patient-specific iPSCs for disease mod-
eling and opens doors for future high-throughput screens.
Results
Derivation and characterization of HD-iPSC lines
To derive the iPSC lines, we retrovirally introduced the
four reprogramming factors (Oct3/4, Sox2, c-MYC and
Klf4) [26,27] into dermal fibroblasts harvested from a male
patient with adult onset HD (50 CAG repeats), his daugh-
ter with juvenile-HD (109 CAG repeats) and non-related
neonatal foreskin fibroblasts (28 CAG repeats) as controls.
Colonies generated from all three fibroblast cell lines
exhibited typical iPSC morphology (Figure 1A), similar to
conventional hESC lines and maintained a normal karyo-
type after continuous expansion (Figure 1B). All cell lines
highly expressed alkaline phosphatase (Figure 1C) and
hESC makers Nanog, OCT3/4, SSEA4 and TRA 1-60
(Additional file 1: Figure S1A). In vitro assessment of plur-
ipotency was performed using an embryoid body assay
whereby the iPSCs were cultured in suspension under
conditions that favored spontaneous differentiation. The
cell lines examined were capable of differentiating into
cells of mesodermal, endodermal and ectodermal origin
(Additional file 1: Figure S1B), confirming in vitro pluripo-
tency. To further evaluate the pluripotency of the iPSC
lines, we utilized a functional in vivo teratoma formation































Figure 1 Characterization of induced pluripotent stem cell lines (iPSCs). A, B: iPSC lines generated from fibroblasts exhibited typical ESC
morphology by phase contrast microscopy (A) and maintained a normal karyotype (B). C: iPSCs strongly expressed the pluripotency marker
alkaline phosphatase, whereas the surrounding MEFs were negative. D: Hematoxylin and eosin staining of teratomas derived from iPSC lines
confirmed pluripotency by the presence of tissues representing the three major germ layers: ectoderm, endoderm, mesoderm. Scale bars:
100 μm.
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ent with teratomas. Tissues representative of the three
major germ layers were detected in each tumor
(Figure 1D). In addition, we also confirmed the expression
of both wild-type and mutant HTT protein in the HD-
daughter fibroblasts and derived iPSCs with Western blot
analysis (Additional file 1: Figure S1C).
HD iPSC-derived neural progenitors form functional
neurons in vitro
To assess the neurodevelopmental potential of the HD-
iPSC lines, we employed two approaches to differentiateiPSCs into neurons: a feeder-free method using an iPSC-
aggregate intermediate to form neural progenitors [36]
and a co-culture protocol that uses a mouse stromal cell
line to induce neural differentiation [37]. For the feeder-
free method, iPSC colonies were grown in suspension in
the presence of neural induction medium to generate
neurospheres that could be maintained and further pas-
saged (Figure 2A). When plated on poly-l-ornithine-lam-
inin (PLO) coated plates, neurospheres attached and
formed neural rosettes expressing neural progenitor
marker nestin (Figure 2B). The neural rosettes gave rise













































Figure 2 Differentiation of D-HD-iPSCs into neural progenitors, immature and mature functional neurons. A: A sample image of a
neurosphere generated from the D-HD-iPSC line using the feeder-free differentiation protocol. B: Nestin-positive neural progenitors displaying
rosette formation and immature (TUJ1+) neurons. C: Phase contrast image of neurons derived from D-HD-iPSCs. D: Mature (MAP2ab+) and
doublecortin (DCX+) expressing neurons. E: Neural progenitor derived from D-HD-iPSCs using the PA6 cell line. Stromal cell monolayer observed
in the background. F: Large networks of TUJ1+ neurons emanating from neural progenitors using the PA6 stromal cell line for induction. Scale
bars: 100 μm. G: D-HD-iPSC derived neurons express both mutant and wild type HTT proteins by Western blot analysis. H: Action potentials
recorded from neurons derived from D-HD-iPSCs and from C1-iPSCs. I: Miniature excitatory post-synaptic currents (mEPSCs) recorded from
iPSC-derived neurons.
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the neural progenitors cells were dissociated into single
cell suspension and plated on PLO coated plates or cov-
erslips in the presence of neural differentiation medium.
Differentiated cells exhibited a typical neuronalmorphology (Figure 2C) and expressed neuronal mar-
kers microtubule associated protein 2ab (MAP2ab) and/
or doublecortin (DCX; Figure 2D). No significant mor-
phological differences were observed for neurons gener-
ated from either F-HD-iPSCs or D-HD-iPSCs under the
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control C1-iPSCs.
For the co-culture method of neural differentiation,
iPSCs were mechanically dissociated into small colonies
and seeded onto the mouse stromal cell line PA6, which
has been shown to induce neural differentiation of
hESCs [37,38]. Within one week of culture on PA6,
iPSCs differentiated into colonies with characteristic
neural progenitor morphology (Figure 2E). After three
weeks of co-culture, many cells exhibited neuronal
morphology and expressed TUJ1 (Figure 2F). Both HD-
and C1-iPSCs were capable of differentiating into neu-
rons via co-culture with the PA6 stromal cell line.
Furthermore, both wild-type and mutant HTT proteins
were expressed in neural progenitors and neurons
derived from the D-HD-iPSCs by Western blot analysis
(Additional file 1: Figure S1C and Figure 2G).
To assess physiological properties of neurons derived
from the HD-iPSCs, we performed electrophysiological
analysis. Neural progenitor cells derived from each cell
line were dissociated into single-cell suspension and pla-
ted on a monolayer of rat hippocampal astrocytes for
three weeks [39]. Whole-cell patch-clamp recordings
showed that neurons from HD-iPSCs exhibited evoked
action potentials; similar to those elicited by C1-iPSCs-
derived neurons (Figure 2H). Miniature excitatory
post-synaptic currents were also detected for HD-
iPSC-derived neurons, providing evidence of functional
synaptic transmission (Figure 2I). We did not detect
overt neuronal functional defects or alterations under the
same experimental conditions from either HD-iPSCs.HD-iPSC-derived neural progenitors engraft, survive and
generate neurons in vivo
We next investigated the short-term in vivo engraftment
potential of HD-iPSC-derived neural progenitor cells by
transplanting them into the adult mouse brain. To allow
for identification of transplanted cells, we expressed
green fluorescent protein (GFP) in F-HD-iPSCs and dif-
ferentiated them into neural progenitors via the feeder-
free method (Figure 3A). Neural progenitor cells were
stereotaxically injected into the dorsolateral area of sub-
ventricular zone (SVZ) of the lateral ventricles of adult
immunecompromised mice (Figure 3B). Adult SVZ pro-
vides a neurogenic microenvironment and newly gener-
ated neurons from endogenous neural progenitors at
SVZ migrate towards the olfactory bulb along a route
termed the rostral migratory stream (RMS) [40]. At six
to eight week post-transplantation, GFP+ cells were
found in the RMS (Figure 3C) and the olfactory bulb
(Figure 3D) and were positive for human nuclei antibody
(HNA), confirming that GFP+ cells were originated from
transplanted human neural progenitor cells. In addition,some GFP+ cells were positive for the neuron-specific
nuclear marker NeuN in the olfactory bulb and exhib-
ited morphology typical of mature granule cells
(Figure 3E). Thus, neural progenitors derived from HD-
iPSCs survive and are capable of differentiating into neu-
rons within the adult mouse brain in vivo.
Astrocytes derived from HD-iPSCs exhibit increased
cytoplasmic vacuolation
Astrocytes have been shown to exhibit non-cell-autonomous
effects on neurons when expressing a HTT protein with a
polyglutamine expansion [22,23]. To examine the driect
effect of mutant HTT on astrocytes, we differentiated neural
progenitors into astrocytes by culturing in the astrocyte
medium (Figure 4A). Cells were continually passaged and
maintained in the astrocyte medium until they exhibited
typical astrocyte morphology. All three iPSC lines were
capable of differentiating with similar efficiency into cells
that expressed the astrocyte markers glial fibrillary acidic
protein (GFAP) and S100β (Figure 4B).
In contrast to the absence of an obvious cellular
phenotype of neurons with a HTT mutation, we
detected a rapid accumulation of discrete clear vacuoles
of variable number and size within the cytoplasm of
astrocytes derived from D-HD-iPSCs (Figure 5A). Simi-
lar vacuoles were observed in lower numbers in astro-
cytes derived from the F-HD-iPSCs. However, vacuoles
were rarely observed in C1-iPSC derived astrocytes
(Figure 5A). Next, we quantified the percentage of astrocytes
that contained cytoplasmic vacuoles. One day after plat-
ing, 24% of astrocytes derived from the D-HD-iPSCs
already contained cytoplasmic vacuoles, compared to
2.7% of astrocytes derived from the F-HD-iPSCs and
1.1% of control astrocytes (600 cells per line; 4 different
experiments). After seven days, the numbers of D-HD
astrocytes with cytoplasmic vacuoles increased to 34%,
compared to 2.7% of HD-father astrocytes and 1.1% of
astrocytes derived from control iPSCs (Figure 5B; 600
cells per line; 4 different experiments).
The cytoplasmic vacuoles were negative for the inter-
mediate filament protein GFAP and appeared empty
(Figure 5C). To determine whether the cytoplasmic
vacuoles were autophagosomes, we performed immuno-
cytochemistry for the marker Light Chain 3 (LC3) that
binds to autophagocytic membranes [41]. Under basal
culture conditions, LC3 staining was weakly detected
within the cytoplasm of astrocytes, but rarely colocalize
with cytoplasmic vacuoles (Figure 5D). To enhance the
detection of autophagosomes, we treated astrocytes
overnight with chloroquine, a drug that accumulates in
lysosomes and prevents fusion of lysosomes with autop-
hagosome by altering lysosomal pH. Chloroquine treat-
ment significantly increased the number of cytoplasmic




















































Figure 3 Transplantation and engraftment of neural progenitors derived from F-HD-iPSCs into the adult mouse brain. A: Neurospheres
derived from F-HD-iPSCs expressing GFP prior to transplantation (phase contrast and fluorescence demonstrating GFP expression). B: A diagram
illustrating neural progenitor cell transplantation. GFP-labeled neural progenitor cells were injected into the subventricular zone (SVZ) and
migrated along the rostral migratory stream (RMS) to the olfactory bulb (OB). GFP and human nuclei antibody (HNA) positive neurons were
detected in the RMS (C) at six weeks and in the OB (D) at eight weeks post-transplantation. E: NeuN+ GFP expressing cells exhibiting granule cell
morphology were detected in the OB eight weeks post-transplantation. Unless otherwise indicated, scale bars: 100 μm.
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The chloroquine-induced vacuoles were mostly autophag-
somes that were positive for LC3. However, LC3 did not
colocalize with all of the cytoplasmic vacuoles observed
(Figure 6B), suggesting the existence of a different type of
vacuoles that might associate with the HTT mutation in
astrocytes.
To further characterize the cytoplasmic vacuolation
observed in HD-astrocytes, we performed transmissionelectron microscopy (TEM). Ultrastructural examination
of astrocytes confirmed the presence of numerous elec-
tron clear vacuoles with variable size and shape
(Figure 7A). Autophagic vacuoles containing 1-2 myelin
whorls were also detected within the cytoplasm of cells,
but with much lower abundance (Figures 7B and 7C).
Occasionally, we also observed astrocytes with clear
empty vacuoles (Figure 7D), autophagosomes (Figure 7E)
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Figure 4 Generation of astrocytes from iPSCs. A: A multi-step protocol was used to generate astrocytes. iPSCs were initially differentiated into
neurospheres using a feeder-free protocol and subsequently differentiated into astrocytes. B: Astrocytes generated from HD-iPSCs exhibited a



































Figure 5 Astrocytes generated from the D-HD-iPSCs with increased cytoplasmic vacuolation. A: Vacuoles were detected in the cytoplasm
of astrocytes (arrows) under phase contrast microscopy. The number of vacuoles varied depending on the iPSC line used to generate the
astrocytes. B: Quantification of cytoplasmic vacuolation. Values represent mean+ SEM (n = 4; *: P< 0.0001; ANOVA). C: Cytoplasmic vacuoles
appeared empty and were negative for GFAP staining. D: The autophagosomal marker LC3 was weakly detected in astrocytes grown under
normal culture conditions and rarely colocalized with cytoplasmic vacuoles. Vacuoles often appeared empty (arrows). Scale bars: 50 μm.




































Figure 6 Enhanced vacuoles formation in astrocytes after chloroquine treatment. A: Overnight treatment of astrocytes with the autophagy
inhibitor chloroquine resulted in increased cytoplasmic vacuolation for all cell lines examined, with D-HD-astrocytes exhibiting the largest number
of vacuoles. B: S100β expressing astrocytes exhibited increased cytoplasmic staining with the autophagic vacuole marker LC3, after treatment
with chloroquine. Scale bar: 50 μm.
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with chloroquine increased the numbers of vacuoles
detected within the cytoplasm of astrocytes and many
had the appearance of lysosomes that were not electron
clear (Figures 7G, 7H, and 7I). Together, these studies
suggest that astrocytes with an HTT mutation exhibit aA B
D E Autophagocy
G H+ Chloroquine + Chlo
* *
*
Figure 7 Ultrastructural changes in astrocytes derived from D-HD-iPS
cytoplasm of astrocytes. B, C: A few autophagocytic vacuoles with myelin w
many empty cytoplasmic vacuoles. Higher magnification revealed an autop
cytoplasmic granules representing lipid droplets (F). G, H, I: Chloroquine tr
proliferation of lysosomes. Scale bars: 2 μm (A-D, G, H) or 500 nm (E, F, I).rapid accumulation of electron clear vacuoles in a CAG-
dose-dependent manner.
Discussion
HD is a devastating neurological disorder for which
there is currently no cure and few therapeutic options.C
F Lipid Dropletstic vacuoles
Iroquine + Chloroquine
C. A: Numerous electron clear vacuoles were observed within the
horls (arrows) in astrocytes. D: Sample image of an astrocyte with
hagocytic vacuole with myelin whorls (E) and large spherical
eated astrocytes exhibited numerous cytoplasmic vacuolation and
Juopperi et al. Molecular Brain 2012, 5:17 Page 9 of 14
http://www.molecularbrain.com/content/5/1/17Given the severity of HD, there is a great need for model
systems that can be used to further our understanding
of the pathogenesis of this disease and as screening tools
to discover or evaluate therapeutic compounds. In this
study, we developed an in vitro model system derived
from cells harvested from HD patients with unique gen-
etic relationship between iPSC lines. One iPSC line was
derived from a male carrying an HTT mutation with 50
CAG repeats and with adult onset HD. The second line
was derived from his daughter with an HTT mutation of
109 CAG repeats and with juvenile onset HD. Trinu-
cleotide repeat length frequently increases in the off-
spring of affected fathers, a phenomenon that is
accentuated with longer paternal repeat lengths and that
accounts for genetic anticipation [15,16]. The underlying
mechanism for this genetic instability is not well under-
stood. The HD-iPSCs of a father and child pairs, includ-
ing cells from the father and the daughter reported here,
could potentially be used as a model system to examine
this intriguing phenomenon.
The HD-iPSC lines derived in this study exhibit typical
hESC morphology, express pluripotency markers, main-
tain a normal karyotype and generate teratomas in vivo
[42]. All lines were able to form neural progenitor cells,
which in turn terminally differentiated in vitro into
phenotypically normal, functional neurons that could
fire action potentials and exhibit functional synaptic
transmission. Although mutant HTT protein was
present in HD-iPSC-derived neurons, an abnormal neur-
onal phenotype was not detected under basal conditions
[43]. The lack of an obvious abnormality at the neuronal
level under normal conditions has been previously
reported by investigators utilizing HD-iPSCs [44]. More-
over, a general lack of neuronal phenotype has indicated
in studies using iPSCs derived from patients with other
neurodegenerative diseases, such as dopaminergic neu-
rons for Parkinson’s disease (PD) [45] and motor neu-
rons for ALS [46]. These findings suggest that simply
directing iPSCs to a specific neuronal subtype may not
be sufficient to produce disease phenotype for certain
aging-dependent neurological disorders and that exten-
sive environmental manipulation or extended observa-
tion in culture may be required. For instance, cellular
stressors leads to toxicity of HD iPSC-derived neurons
under medium spiny neuron differentiation protocol
[43]. The environmental cues needed to induce neurode-
generation in HD patients may be complex, requiring an
intricate milieu of growth factors, morphogens and ap-
propriate stressors. It may be necessary to further define
the in vitro culture conditions to fully recapitulate the
neuronal pathology observed in patients, such as the for-
mation of HTT cellular inclusions.
The inability to maintain human neurons for long
period of time has limited our ability to model late onsetneurological diseases in culture; however, the develop-
ment of patient specific iPSC technology has opened up
the possibility of combining animal model systems with
cell transplantation for longitudinal studies. We assessed
the short-term in vivo engraftment capability of F-HD-
iPSCs. We demonstrated that neural progenitors derived
from F-HD-iPSCs transplanted into neurogenic SVZ of
adult NOD-SCID mice were able to migrate along the
RMS and generate neurons in the olfactory bulb. Im-
portantly, the HD-iPSC derived cells were able to survive
in the mouse brain for at least eight weeks post-
transplantation. The results of our xenotransplantation
experiments provide a foundation for future long-term
engraftment studies and such a system could potentially
be utilized to evaluate long term neuronal survival and
degeneration in vivo and as a preclinical in vivo model
for testing of therapeutic treatments.
Astrocytes are an abundant cell type in the adult brain
and they perform essential and complex functions such
as providing metabolic and trophic support for neurons,
as well as overall structural support [47,48]. Astrocyte
dysfunction has been implicated in the pathogenesis of
several neurodegenerative diseases, including ALS
[49,50], PD [51] and Alzheimer’s disease [52]. The contri-
bution of astrocytes to the development and progression
of HD remains to be elucidated [9,22]. Recent studies
have shown that expression of mutant N-terminal Hun-
tingtin fragment in astrocytes suppresses BDNF secretion
[53]. One of the advantages of using patient-derived
iPSCs to develop an in vitro experimental system is the
ability of the iPSC to generate any cell types of interest
[31]. We utilized the pluripotent property of iPSCs and
differentiated them into GFAP+ and S100β+ astrocytes.
Strikingly, discrete, variably sized, clear vacuoles were
detected within the cytoplasm of astrocytes derived from
both HD-iPSCs, with D-HD-astrocytes had significantly
higher number of cytoplasmic vacuoles. When examined
by electron microscopy, the cytoplasm contained clear
vacuoles that appeared empty, in addition to lower num-
bers of autophagic vacuoles and lipid droplets. Interest-
ingly, cytoplasmic vacuolation has been observed in
primary lymphoblasts harvested from individuals with
HD and a correlation was found between the CAG
repeat-length and the number of cytoplasmic vacuoles
[54,55]. Consistent to what we observed in astrocytes,
ultrastructural findings of the lymphoblasts were found
to exhibit increased numbers of empty vesicles, autopha-
gocytic vacuoles and lipid droplets.
Successful modeling of neurological disorders using
iPSC technology have been reported, but mainly with
neurodevelopmental disorders, such as spinal muscular
atrophy [56], Rett syndrome [57] and familial dysautono-
mia [58]. Although many disease-specific iPSC lines for
neurodegenerative diseases have been generated, few
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phenotype [31]. In our study, we identified a phenotype
in astrocytes generated from iPSCs derived from patients
with the neurodegenerative disorder HD. Notably, this
phenotype was detected under basal conditions without
additional stressors. Importantly, the characteristics of
vacuoles in astrocytes was consistent with those seen in
primary lymphoblasts harvested from HD patients
[54,55], suggesting cellular vacuolation may be a disease
associated abnormality that may be used as a biomarker
for HD. Future studies will focus on further determining
the disease-relevance and mechanistic studies to explore
the relationship of the phenotype to HD pathogenesis.
Conclusion
We have derived patient specific iPSCs from a daughter
and her father affected with HD, which provide a unique
in vitro system to study HD, a defined, genetic, neurode-
generative disorder. The iPSCs from both diseased cell
lines were differentiated into neural progenitor cells and
further into functional neurons in vitro, and give rise to
neurons in the adult mouse brain after transplantation
in vivo. Astrocytes derived from HD iPSCs exhibit
increased cytoplasmic vacuolation. Most importantly,
we were able to recapitulate a phenotype under basal
conditions that has previously been documented in pri-
mary cells harvested from HD patients. These results
pave the way for future mechanistic studies of HD
pathogenesis, disease modeling and for high-throughput
therapeutic screens.
Methods
Induced pluripotent stem cell derivation and
characterization
Skin biopsies were obtained from a male patient with adult
onset Huntington’s disease (50 CAG repeats) and his
daughter with juvenile onset HD (109 CAG repeats). Der-
mal fibroblast cultures were established from skin biopsies
for iPSC derivation as previously described [59]. Unrelated
neonatal foreskin fibroblasts were acquired from Ameri-
can Type Culture Collection (CRL-2097, 28 CAG repeats)
for generation of control iPSCs. iPSC lines were derived
by retroviral transduction of the four factors (Oct3/4,
Sox2, c-MYC and Klf4) according to previously published
methods [60]. The iPSC lines were maintained on irra-
diated mouse embryonic fibroblasts (MEF) in hESC
medium (hESM) consisting of Dulbecco’s modified Eagle
medium (DMEM)/F12 (Invitrogen) supplemented with
20% Knock-out serum replacement (KOSR, Invitrogen),
2 mM L-glutamine, 0.1 mM β-mercaptoethanol, 0.1 mM
non-essential amino acids solution (NEAA), and 8 ng/ml
of recombinant human basic fibroblast growth factor
(bFGF, Preprotech). G-banding for karyotype analysis was
performed for all iPSC lines by the Cytogenetics Core ofthe Johns Hopkins Medical Institution. All procedures fol-
lowed approved protocol by Institutional IRB and ISCRO
Committees.
Pluripotency marker expression was assessed with
immunohistology as previously described [59,61]. Cells
were fixed with 4% paraformaldehyde for ten minutes at
room temperature, washed with phosphate buffered sa-
line (PBS) and blocked with 10% donkey serum in
0.25% Triton X-100 in PBS for one hour. Specimens
were incubated in a solution of 1% donkey serum in
PBS overnight at 4°C with the following primary anti-
bodies: goat anti-Nanog (R&D Systems, 1:250), mouse
anti-TRA 1-60 (Millipore, 1:250), mouse anti-SSEA4
(Millipore, 1:400), mouse anti-OCT3/4 (Santa Cruz,
1:400). Following three washes with PBS, the samples
were incubated with the appropriate secondary antibody
in PBS with 1% donkey serum for one hour at RT. Sam-
ples were washed with PBS and counter-stained with
4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI)
to visualize the nuclei. FITC- and Cy3-conjugated sec-
ondary antibodies were obtained from Jackson Immu-
noResearch. Images were acquired with confocal
microscopy system. Alkaline phosphatase activity was
detected using SigmaFAST BCIP/NBT kit (Sigma)
according to the manufacturer instructions.
For in vitro assessment of pluripotency, an embryoid
body assay was performed as previously described [59].
iPSCs were enzymatically detached from MEF by incu-
bation with collagenase IV (Invitrogen). The colonies
were washed with PBS (Invitrogen), re-suspended and
cultured in suspension using ultra-low attachment
plates (Corning). After two days, the medium was
changed to DMEM/F12 supplemented with 20% fetal
bovine serum (FBS, HyClone) 2 mM L-glutamine,
0.1 mM β-mercaptoethanol, 0.1 mM NEAA. Two
weeks after the initiation of embryoid body formation,
the aggregates were cultured on gelatin coated plates
to allow for attachment, outgrowth and further differ-
entiation. Primary antibodies used for germ-layer
evaluation included: mouse anti-human α-fetoprotein
(Millipore, 1:250), rabbit anti-nestin (Millipore,1:250)
and mouse anti-human α-smooth muscle actin
(Millipore,1:500).
To assess the in vivo pluripotency of iPSC lines
generated, teratoma formation assays were performed
as previously described [62]. Four to six week old fe-
male NOD.CB17-Prkdcscid/J mice (Jackson Laboratory)
were injected subcutaneously into the dorsal flank
with cells collected from one confluent six-well plate.
Cells were harvested by incubation with collagenase
IV (Sigma) and resuspended in DMEM/F12 medium
supplemented with 30% Matrigel (BD Biosciences).
Animals were monitored frequently and visible tumors
were excised between eight to 12 weeks post-injection.
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malin, paraffin embedded, sectioned and stained with
hematoxylin and eosin for histological evaluation. All
animal procedures were approved by the Animal Care
and Use Committee at Johns Hopkins University
School of Medicine.Assessment of HTT expression
For determination of HTT expression, cell lysates were
prepared in RIPA buffer (1%NP-40, 0.1% SDS, 0.5% so-
dium deoxycholate in PBS) with protease inhibitor cocktail
tablets (Roche). Protein concentrations were determined
using the Pierce BCA protein assay kit (Thermo Scientific).
To ensure separation of the wild-type and mutant HTT
proteins, precast 3-8%Tris-Acetate gels (Invitrogen) were
run at 70V for 30 minutes followed by 110V for 9 hours at
4°C. Western blot analysis was performed using mouse
anti-HTT antibody (Millipore MAB 2166, 1:10000) and
donkey anti-mouse HRP conjugated secondary antibodies
(Jackson ImmunoResearch, 1:5000).Neural differentiation of iPSCs and assessment of
functionality
Neural differentiation of iPSCs was performed using two
methods: a feeder-free and a feeder-dependent method.
We used a modified version of a previously described
feeder-free method [36]. Briefly, iPSCs were enzymatically
detached from MEF by incubation with collagenase IV.
The colonies were washed with PBS, re-suspended in
hESM supplemented with 20 ng/ml of bFGF and cultured
in suspension using ultra-low attachment plates. After five
days, the medium was changed to a neural-induction
medium consisting of neurobasal medium (Invitrogen)
supplemented with 2% B27 (Invitrogen), 1% glutamine,
and 40 ng/ml of bFGF. Partial media change was per-
formed every second day and colonies were observed for a
neurosphere morphology. For terminal differentiation into
neurons, neural progenitor cells were mechanically disso-
ciated by trituration to a single cell suspension and plated
on poly-L-ornithine (Sigma, 20 μg/ml) and laminin (BD
Biosciences, 10 μg/ml) coated coverslips in 24-well plates
at a concentration of 30,000 cells/well. To initiate differen-
tiation, dissociated neural progenitor cells were cultured
in neural induction medium without bFGF (neural differ-
entiation medium). Culture medium was changed every
three to five days and cells were monitored frequently for
neuronal growth. In the absence of bFGF, neuronal differ-
entiation was observed at one week post-plating. To con-
firm neural differentiation, following primary antibodies
were used: mouse anti-Nestin (Chemicon, 1:250), rabbit
anti-β-tubulin (TUJ1; Sigma 1:2000), mouse anti-MAP2ab
(Sigma, 1:250) and goat anti-DCX (Santa Cruz Biotechnol-
ogy, 1:500).For neural differentiation via the feeder-dependent
method, the PA6 stromal cell line (RIKEN) was utilized
according to a previously published protocol [37]. PA6 cells
were maintained in Minimum essential medium alpha
medium (Invitrogen) supplemented with 10% FBS and 1%
penicillin-streptomycin (P/S). Once the stromal cell line
had formed a confluent monolayer, it was used for neural
differentiation. iPSCs were mechanically harvested from
MEFs using the STEMPRO EZPassage tool (Invitrogen),
washed with PBS and resuspended in neural induction
medium consisting of Glasgow minimum essential medium
(Invitrogen), 10% KOSR, 2 mM L-glutamine, 1 mM sodium
pyruvate and 0.1 mM β-mercaptoethanol and 1% P/S. Small
iPSCs colonies were seeded onto the PA6 monolayer and
medium was changed every three days. The cultures were
monitored daily for neuronal differentiation.
To assess neuronal function, electrophysiology of neurons
derived from control iPSCs and HD-derived iPSCs was per-
formed as previously described [39]. Neural progenitors
derived by the feeder-free method were dissociated by tritur-
ation and single cells plated onto a layer of rat hippocampal
astrocytes [47,63,64]. For whole-cell patch-clamp recordings,
the patch pipette (3–7 MΩ) was filled with the following in-
ternal solution to record action potentials and mEPSCs: (in
mM) K-gluconate 130, KCl 4, HEPES 10, EGTA 2, ATP 4,
GTP 0.3, and phosphocreatine 7 (pH 7.3) and the external
solution had the following composition (in mM): NaCl 140,
KCl 3, CaCl2 2, MgCl2 1.3, HEPES 10, and glucose 10 (pH
7.4). For mEPSC recordings, 10 μM bicuculline and 1 μM
tetrodotoxin was added to the external solution. An Axo-
patch 200B amplifier (Axon Instruments/Molecular Devices
Corp., Union City, CA) was used for neuron recordings and
analyzed using Clampfit 9.02 (Axon Instruments). Data were
digitized at 10 kHz with a 2 kHz low-pass filter.
Transplantation of iPSC-derived neural progenitors and
assessment of engraftment
GFP+ neurospheres derived from the F-HD-iPSC line were
mechanically dissociated into a single-cell suspension by
trituration with a pipette tip. Cells were pelleted by centri-
fugation and re-suspended in Neurobasal medium at a
concentration of 100,000 cells/μl. Four to six week-old fe-
male NOD.CB17-Prkdcscid/J mice were used as transplant-
ation recipients. Mice were anesthetized and 400,000 cells
were stereotaxically injected into the subventricular zone
of each mouse (4 μl/site; AP: 1 mm, ML: 1 mm, DV: 2 mm
from Bregma). Mice were sacrificed at three, six and eight
weeks of age to assess engraftment of the neural progenitor
cells. Brain sections were prepared from transplanted mice
and processed for immunostaining as described [65,66].
The following primary antibodies were used for immuno-
histochemistry: mouse anti-NeuN (Chemicon, 1:500),
rabbit anti-GFP (1:1000) and mouse anti-human nuclei
(HNA,Millipore, 1:100). Images were acquired on a META
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multi-track configuration. Procedures were performed in
accordance with the Animal Care and Use Committee at
Johns Hopkins University.
Astrocyte differentiation of iPSCs and characterization
Neurospheres derived using the feeder-free method were
mechanically dissociated into a single cell suspension, fil-
tered through a cell strainer and plated on poly-L-ornithine
-laminin coated flasks. Cells were cultured in Astrocyte
medium (ScienCell) and passaged as necessary. Once cells
exhibited astrocyte morphology and formed a continuous
monolayer, they were evaluated for the expression of astro-
cyte markers by immunocytochemistry using rabbit anti-
GFAP (Dako, 1:500) and mouse anti-s100β (Sigma, 1:500).
To quantify the number of astrocytes with cytoplasmic
vacuolation, 600 randomly chosen cells were examined for
each cell line and the average percentage of cells with
vacuoles for four experiments was determined. Astrocytes
were also examined for the presence of autophagosomes by
immunostaining for the autophagy marker LC3 using rabbit
anti-LC3 A/B (Cell Signaling, 1: 200). To induce autopha-
gosome formation, astrocytes were treated with 50 μM
chloroquine diphosphate (Invitrogen) overnight.
Transmission electron microscopy (TEM)
Cells were fixed in 2.5% glutaraldehyde, 3mM CaCl2, 1%
sucrose, in 0.1 M sodium cacodylate buffer (pH 7.2) for one
hour at RT. After a buffer rinse, samples were post-fixed in
1% osmium tetroxide in buffer (1 hour) on ice in the dark.
Specimens were stained with 2% aqueous uranylacetate,
dehydrated in a graded series of ethanol and embedded in
Eponate 12 (Ted Pella) resin. Samples were polymerized at
60°C overnight. Ultrathin sections were prepared with a
diamond knife on the Reichert-Jung Ultracut E ultramicro-
tome and picked up with naked 200 mesh copper grids.
Grids were stained with 2% uranyl acetate in 50% methanol
and cells were observed with a Hitachi 7600 TEM at 80 kV.
Images were captured with an AMT CCD (1K x 1K) cam-
era. TEM was performed at the Johns Hopkins Institute for
Basic Biomedical Sciences microscope facility.
Additional file
Additional file 1: Figure S1. In vitro characterization of the
D-HD-iPSCs. A: Expression of pluripotency markers. Immunostaining for
the nuclear markers nanog and octamer-binding transcription factor 3/4
(OCT3/4) and the cell surface markers TRA 1-60 and stage specific
embryonic antigen 4 (SSEA4) were positive. B: In vitro pluripotency was
confirmed using an embryoid body assay to generate cells derived from the
three major germ layers. Alpha-fetoprotein (AFP) positive cells representing
endoderm, smooth muscle actin (SMA) expressing cells representing
mesoderm and nestin positive cells representing ectoderm were identified.
Scale bars: 100 μm. C: Western blot analysis confirmed the expression of
mutant and wild-type HTT proteins in fibroblasts, iPSCs and neurospheres
derived from the D-HD-iPSC. The hESC line H1 only expresses one band,
corresponding to the wild-type protein.Competing interests
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